Kathryn Dunne
Research Subjects
Kathryn Dunne has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Wardley
The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK
18 shared publications - Iain Rj Macpherson
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
18 shared publications - Judith Margaret Bliss
Institute of Cancer Research 5 Clinical Trials Unit London, United Kingdom
18 shared publications - Lucy Kilburn
Clinical Trials and Statistics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
18 shared publications - Matthew Winter
Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
18 shared publications - Nicholas C. Turner
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
18 shared publications
Latest Publications
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Characteristics of c-TRAK TN patient population in the full cohort (Total) and those with samples available for cross assay comparison.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Characteristics of c-TRAK TN patient population in the full cohort (Total) and those with samples available for cross assay comparison.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Correlation between the tumor fraction percentage as reported by mean Variant Allele Frequency (mean VAF) or estimated Variant Allele Frequency (eVAF) for the RaDaR ctDNA assay.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Correlation between the tumor fraction percentage as reported by mean Variant Allele Frequency (mean VAF) or estimated Variant Allele Frequency (eVAF) for the RaDaR ctDNA assay.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Comparison of median lead time from ctDNA detection to relapse between dPCR and RaDaR assays using paired data in all individuals with relapse (n=40).
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Comparison of median lead time from ctDNA detection to relapse between dPCR and RaDaR assays using paired data in all individuals with relapse (n=40).
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Representativeness of the study population
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Representativeness of the study population
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Rate of concordance and discordance between RaDaR and dPCR assays that tracked one or two variants, by sample
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Rate of concordance and discordance between RaDaR and dPCR assays that tracked one or two variants, by sample
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Diagnostic performance of RaDaR assay at 24 months.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Diagnostic performance of RaDaR assay at 24 months.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Rate of concordance and discordance between RaDaR and dPCR assays that tracked one or two variants, by sample
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Rate of concordance and discordance between RaDaR and dPCR assays that tracked one or two variants, by sample
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Characteristics of the ChemoNear patient population selected for pilot study.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Characteristics of the ChemoNear patient population selected for pilot study.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Characteristics of c-TRAK TN patient population in the full cohort (Total) and those with samples available for cross assay comparison.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer
Characteristics of c-TRAK TN patient population in the full cohort (Total) and those with samples available for cross assay comparison.